Background {#Sec1}
==========

Carbapenems are considered the most effective antibacterial agents against infections caused by multi-drug resistant gram-negative bacillus in clinical practice. However, with the broad use of carbapenems, and the emergence and widespread of carbapenem-resistant *Enterobacteriaceae* (CRE), in particular carbapenem-resistant *Klebsiella pneumoniae* (CR-KP), the clinical anti-infection treatment faces a drug-free dilemma \[[@CR1]--[@CR4]\]. Previous studies have shown that the most important resistant mechanism of CR-KP to carbapenems is production of carbapenemases including class A KPC carbapenemases, class B metallo-β-lactamases and class D OXA-48 family carbapenemases. Avibactam is a newly developed novel β-lactamase inhibitor in recent years and can efficiently inhibit class A and class D carbapenemases. As an inhibitor, avibactam can restore the antibacterial activity of ceftazidime to CR-KP. Nevertheless, it has less antibacterial efficiency against CR-KP with metallo-β-lactamase \[[@CR5]--[@CR7]\]. Knowing that aztreonam is stable against hydrolysis by class B metallo-β-lactamases, we hypothesized that supplement of aztreonam to the ceftazidime-avibactam would enhance the activity by "protecting" aztreonam from the "attack" of KPC type carbapenemase. This study aims to explore a new therapeutic regimen by administration of ceftazidime-avibactam alone or combined with aztreonam against carbapenemase-producing *Klebsiella pneumoniae*.

Materials and methods {#Sec2}
=====================

Strains {#Sec3}
-------

A total of 47 non-repeated clinical strains of carbapenemase-producing *Klebsiella pneumoniae* were collected from 9 hospitals in 9 cities in China. Of these, 16 strains were *bla*~KPC-2~ positive, 1 was *bla*~OXA-232~ positive, 28 were *bla*~NDM~ positive, and 2 were *bla*~KPC2~ coupled with *bla*~NDM~ positive *Klebsiella pneumoniae*. All strains were identified by mass spectrometry and the gene type of carbapenemases was analyzed by PCR amplification using primers previously described and DNA sequencing \[[@CR8]--[@CR10]\]. *E. coli* ATCC 25922 were used as quality control strain for antimicrobial susceptibility testing. One *K. pneumoniae* clinical strain Y8 was used for the Infection in the mouse model.

Antimicrobial susceptibility testing {#Sec4}
------------------------------------

The minimal inhibitory concentrations were determined by microbroth dilution according to Clinical and Laboratory Standards Institute (CLSI) guidelines \[[@CR11]\]. The in vitro synergistic bactericidal effects of ceftazidime- avibactam combined with aztreonam against *bla*~NDM~-positive strains were determined by checkerboard assay referred to the published reports \[[@CR12], [@CR13]\]. The calculation and interpretation of fractional inhibitory concentration (FIC) was referred to the document standards \[[@CR14]\]. FIC = MIC ~drug\ A~ / MIC ~drug\ A\ plus\ drug\ B~ + MIC~drug\ B~/ MIC ~drug\ A\ plus\ drug\ B~. FIC ≤ 0.5 was considered as a synergistic effect, 0.5 \< FIC ≤ 1 was considered as an additive effect, 1 \< FIC ≤ 2 was considered as an irrelevant effect, and \> 2 was considered as an antagonism.

Time-kill assay {#Sec5}
---------------

According to the minimal inhibitory concentration (MIC) of ceftazidime-avibactam to *bla*~KPC-2~ or *bla*~OXA-232~ producers, the bactericidal effects of ceftazidime-avibactam at various concentrations of 0.5MIC, 1MIC, 2MIC, 4MIC and 8MIC were studied by time-kill assay. In line with the results of antimicrobial susceptibility testing of ceftazidime-avibactam combined with aztreonam, and following the methods recommended in literatures \[[@CR15], [@CR16]\], 10 *Klebsiella pneumoniae* strains with *bla*~NDM~ and 2 *Klebsiella pneumoniae* strains with *bla*~NDM~ coupled with *bla*~KPC-2~ were randomly selected for synergistic bactericidal effects. The operation procedure is briefly described as follows: Mueller-hinton broth containing 1 × 10^5^ CFU/mL bacteria is mixed with single or combined antimicrobial agents incubated overnight with consecutive shacking at 35 °C in an atmospheric environment. Meanwhile, the same broth without antibiotics was served as a growth control. Broth samples were serially diluted at times of 0, 2, 4, 6, 8 and 10 h and smeared on a mueller-Hinton plate respectively. After overnight incubation at 35 °C, the colonies were counted. If the reduction of bacterial survival amount in sample treated with combined antibiotics was ≥2 log10 CFU/mL than those in the sample treated by single drug, it was considered to have a synergistic bactericidal effect.

Effect of ceftazidime-avibactam against *K. pneumoniae* strain Y8 infection in the mouse model {#Sec6}
----------------------------------------------------------------------------------------------

Six-week-old BALB/c mice (female) were bought from Shanghai Laboratory Animal Company (SLAC), China. Animal experiments were performed in accordance with the Animal Ethics Committee of Shanghai Jiao Tong University. Groups of 10 mice were infected with 2.5 × 10^6^ CFU of strain Y8 via the intraperitoneal (ip) route. Then mice were treated with PBS (infection group) or ceftazidime-avibactam (treatment group) (0.375 mg/g of body weight in 0.1 ml PBS) by subcutaneous injection 4 h post infection and given every 8 h for 10 days. The survival rates of mice were measured at desired time point to assess the therapeutic efficacy of ceftazidime-avibactam. Survival curves were monitored for 15 days.

Bacterial load in the blood and tissues of mice {#Sec7}
-----------------------------------------------

To measure the efficacy of this drug, the bacterial load was measured in the blood and tissues of mice. Groups of 8 mice were infected with 2.5 × 10^6^ CFU of strain Y8 via the ip and then treated with PBS or ceftazidime-avibactam by subcutaneous injection. The antibiotic dosage and administration were same as the survival experiment mentioned above. At 3 days post infection (dpi), mice in treatment and infected group were euthanized, and the blood and tissues of mice were removed to determine the bacterial burden through bacterial dilution-plate method.

Results {#Sec8}
=======

Antimicrobial susceptibility testing {#Sec9}
------------------------------------

All 16 *Klebsiella pneumoniae* strains with *bla*~KPC-2~ were susceptible to ceftazidime-avibactam with MIC range for 4--8 mg/L. However, all of strains were resistant to ceftazidime with MIC~50~ of 32 mg/L and MIC~90~ of \> 256 mg/L. The resistance rate of imipenem was 93.8% with MIC~50~ and MIC~90~ for 64 mg/L and 128 mg/L, respectively. The resistance rate of meropenem was 93.8% with MIC~50~ and MIC~90~ for 64 mg/L and 256 mg/L, respectively (Table [1](#Tab1){ref-type="table"}). The MIC of ceftazidime-avibactam to one OXA-232 carbapenemase-producing *Klebsiella pneumoniae* was 2 mg/L. The resistance rate of ceftazidime-avibactam to 30 *bla*~NDM~ (including NDM plus KPC-2) positive *Klebsiella pneumoniae* strains was 76.7% with MIC range for 0.5\~ 256 mg/L, MIC~50~ and MIC~90~ for 64 mg/L and 256 mg/L, respectively. The MIC range of aztreonam was 8\~ \> 256 mg/L with MIC~50~ and MIC~90~ were 128 mg/L and \> 256 mg/L, respectively. Ceftazidime-avibactam combined with aztreonam showed synergistic effects to 90% (27/30) of strains with *bla*~NDM,~ 3.3% (1/30) showed additive effects and 6.6%(2/30) showed unrelated effects. No antagonism was found for ceftazidime-avibactam combined with aztreonam (Table [2](#Tab2){ref-type="table"}).Table 1Minimal inhibitory concentration (MIC) of ceftazidime-avibactam against KPC-2 or OXA-232 carbapenemase-producing *Klebsiella pneumoniae*Strain no.Bacteriaβ-lactamaseMIC (mg/L)Associated β-lactamaseCAZ-AVICAZIPMMEMR16- Hefei*K. pneumoniae*KPC-281286464CTX-M-14, SHV-11, DHA-1R18- Hefei*K. pneumoniae*KPC-24128816SHV-28, DHA-1R19- Hefei*K. pneumoniae*KPC-241281616SHV-12, DHA-1R31- Beijing*K. pneumoniae*KPC-2812864256SHV-11, DHA-1R35- Beijing*K. pneumoniae*KPC-28128128256SHV-11, DHA-1R39-Fuzhou*K. pneumoniae*KPC-28\> 2563264CTX-M-14, SHV-12, DHA-1R42- Fuzhou*K. pneumoniae*KPC-28\> 2563264CTX-M-14, SHV-12, DHA-1R44- Fuzhou*K. pneumoniae*KPC-28\> 25664128CTX-M-14, SHV-12, DHA-1R46- Fuzhou*K. pneumoniae*KPC-28\> 2566464SHV-12, DHA-1R52- Fuzhou*K. pneumoniae*KPC-28\> 25664128CTX-M-14, SHV-12, DHA-1R53- Fuzhou*K. pneumoniae*KPC-28\> 25664128CTX-M-14, SHV-12, DHA-1R59- Hangzhou*K. pneumoniae*KPC-2832816CTX-M-14, SHV-11, DHA-1R60- Hangzhou*K. pneumoniae*KPC-243244CTX-M-14, SHV-11, DHA-1JSD-Shanghai*K. pneumoniae*KPC-28128128512CTX-M-14, SHV-11, DHA-1WJQ-Shanghai*K. pneumoniae*KPC-28\> 256128256CTX-M-14, SHV-11, DHA-1LDX-Shanghai*K. pneumoniae*KPC-28\> 2563264CTX-M-55, SHV-31, DHA-1PED-Shanghai*K. pneumoniae*OXA-2322\> 3214CTX-M-15, SHV-1Note: *CAZ-AVI* Ceftazidime-avibactam, *CAZ* Ceftazidime, *IPM* Imipenem, *MEM* MeropenemTable 2Results of MIC and antimicrobial susceptibility testing of ceftazidime-avibactam single dosing and combined with aztreonam against NDM + KPC-2 carbapenemase-producing *Klebsiella pneumoniae* in 30 strainsStrain no.Bacteriaβ-lactamaseMIC(mg/L) single dosingMIC(mg/L) Combined dosingFIC valueAssociated β-lactamaseATMCAZ-AVIATMCAZ-AVIATM + CAZ-AVIR078 Anhui*K. pneumoniae*NDM25632810.06SHV-28, DHA-1, CTX-M-15R080 Hainan*K. pneumoniae*NDM1284320.250.31SHV-11, DHA-1, CTX-M-14R081 Hainan*K. pneumoniae*NDM102486420.31SHV-11, DHA-1, CTX-M-14R082 Hainan*K. pneumoniae*NDM256641610.08SHV-11, DHA-1, CTX-M-15, CTX-M-14R083 Hainan*K. pneumoniae*NDM12864320.50.26SHV-12, DHA-1, CTX-M-15R084 Hainan*K. pneumoniae*NDM512641610.05SHV-12, DHA-1R085 Hainan*K. pneumoniae*NDM10241283220.05SHV-12, DHA-1, CTX-M-15R086 Hainan*K. pneumoniae*NDM12864160.50.13SHV-12, DHA-1, CTX-M-15R088 Hainan*K. pneumoniae*NDM32240.50.38SHV-11, DHA-1, CTX-M-14R093 Hebei*K. pneumoniae*NDM326440.50.13SHV1, DHA-1, CTX-M-14R094 Hebei*K. pneumoniae*NDM326480.250.25SHV-12, DHA-1, CTX-M-14R095 Hebei*K. pneumoniae*NDM32280.250.38SHV-12, DHA-1, CTX-M-15R096 Henan*K. pneumoniae*NDM1664160.51.01SHV1, DHA-1, CTX-M-15R097 Henan*K. pneumoniae*NDM825641281.00SHV1, DHA-1, CTX-M-14R098 Henan*K. pneumoniae*NDM256643210.14DHA-1R100 Shanxi*K. pneumoniae*NDM8324321.50SHV-78, DHA-1, CTX-M-14R101 Shanxi*K. pneumoniae*NDM2561281610.07SHV-78, DHA-1, CTX-M-14R102 Shanxi*K. pneumoniae*NDM32256410.13SHV-78, DHA-1, CTX-M-14R103 Shanxi*K. pneumoniae*NDM12864320.250.25SHV1, DHA-1, CTX-M-15R106 Sanxi*K. pneumoniae*NDM12864810.08SHV-12, DHA-1R110 Sanxi*K. pneumoniae*NDM128256810.07SHV-12, DHA-1R113 Sanxi*K. pneumoniae*NDM12864160.50.13SHV-12, DHA-1R122 Tianjin*K. pneumoniae*NDM32140.250.38SHV-12, DHA-1, CTX-M-14R126 Tianjin*K. pneumoniae*NDM512641610.05SHV-12, DHA-1, CTX-M-14R127 Tianjin*K. pneumoniae*NDM2561283210.13SHV2, DHA-1R128 Zhejiang*K. pneumoniae*NDM128256820.07SHV1, DHA-1R129 Zhejiang*K. pneumoniae*NDM40.50.50.1250.38SHV-12, DHA-1, CTX-M-15R136 Zhejiang*K. pneumoniae*NDM256641610.08SHV-12, DHA-1R148 Tianjing*K. pneumoniae*KPC-2,NDM2048825620.38SHV-12, DHA-1, CTX-M-14R153 Henan*K. pneumoniae*KPC-2,NDM204812812880.13SHV-12, DHA-1

Time-kill assay {#Sec10}
---------------

The results of time-kill assays showed that all *bla*~KPC-2~ or *bla*~OXA-232~ positive *K. pneumoniae* strains rebounded to grow 4 to 6 h at 0.5 MIC of ceftazidime-avibactam. At the concentration of 1 MIC ceftazidime-avibactam, 23.5% (4/17) of strains declined stably 2 h after dosing and no colonies were detected at 24 h, however, 76.5% (13/17) of strains rebounded to grow in 4--6 h. At the concentrations of 2MIC, 4MIC or 8MIC of ceftazidime-avibactam, it showed a significant bactericidal effectiveness for either *bla*~KPC~ or *bla*~OXA-232~ positive *K. pneumoniae* and the colony growth was undetected after 24 h incubation for most of strains (Fig. [1](#Fig1){ref-type="fig"} and Fig. [2](#Fig2){ref-type="fig"}). For *bla*~NDM~ positive *K. pneumoniae*, ceftazidime-avibactam combined with aztreonam showed a significant bactericidal effectiveness and the colony growth was undetected after 10 h incubation (Fig. [3](#Fig3){ref-type="fig"}).Fig. 1Bactericidal curve plots of ceftazidime-avibactam at various concentrations against KPC-2 carbapenemase-producing *Klebsiella pneumoniae*Fig. 2Bactericidal curve plots of ceftazidime-avibactam at various concentrations against OXA-232 carbapenemase-producing *Klebsiella pneumoniae*Fig. 3Bactericidal curve plots of ceftazidime-avibactam combined with aztreonam against NDM carbapenemase-producing *Klebsiella pneumoniae*

Therapeutic efficacy of ceftazidime-avibactam against *K. pneumoniae* strain Y8 infection in mouse {#Sec11}
--------------------------------------------------------------------------------------------------

Mice were infected with 2.5 × 10^6^ CFU of strain Y8 and treated with PBS or ceftazidime-avibactam for 10 days. 70% of infection group mice died within 4 days, and all mice in this group died within 13 days (Fig. [4](#Fig4){ref-type="fig"}). All treatment group mice survived at 10 dpi with the antibiotic applied every 8 h, whereas 100% of mice in this group died within 4 days after the antibiotic treatment stopped (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4Therapeutic efficacy of ceftazidime-avibactam against *K. pneumoniae* strain Y8 infection in mouse. Mice were infected with 2.5 × 10^6^ CFU of strain Y8 via the ip route and then treated with PBS or ceftazidime-avibactam by subcutaneous injection. Their survival was assessed daily for 15 days (*n* = 10). ∗*P* \< 0.05; ∗∗∗*P* \< 0.001

Bacterial load in the blood and tissues of mice {#Sec12}
-----------------------------------------------

Mice were infected with 2.5 × 10^6^ CFU of strain Y8 via the ip and then treated with PBS or ceftazidime-avibactam. The viable bacteria were quantified in blood, liver and spleen at 3 dpi. The results showed that there was no significant difference in the amount of bacteria in the blood between the infected group and the treatment group. However, the spleen and liver of treatment group mice showed lower CFU counts, as compare with that of infected group, indicating that the antibiotic has significant effect on the bacteria and ceftazidime-avibactam led to a certain therapeutic efficacy (Fig. [5](#Fig5){ref-type="fig"}).Fig. 5Bacterial burden in blood, spleen and liver of mice at 3 days post infection (dpi). Mice were infected with 2.5 × 10^6^ CFU of strain Y8 via the ip route and then treated with PBS or ceftazidime-avibactam by subcutaneous injection. At 3dpi, the viable bacteria of blood, spleen and liver was determined by plating serial dilutions on agar plates (*n* = 8). ∗*P* \< 0.05; ∗∗*P* \< 0.01

Discussion {#Sec13}
==========

In the recent decade, the prevalence and dissemination of CR-KP has posed a serious challenge in healthcare facilities in the world. The data from the Centers for Disease Control, USA disclosed the infection incidence of CR-KP increased from 1.2% in 2001 to 4.2% in 2011. In annual of 140,000 cases with *Enterobacteriaceae* infections, 9300 cases (6.6%) were infected by these multidrug-resistant bacteria \[[@CR17]\]. According to CHINET surveillance data, the resistance rate of *Klebsiella pneumoniae* to carbapenems were significantly increasing from 3% in 2005 to 20% in 2017 \[[@CR18]\]. Due to lack of effective antibacterial agents, infections due to CR-KP especially for hypervirulent *Klebsiella pneumoniae* usually accompany with high mortality \[[@CR19], [@CR20]\]~.~ Carbapenemases are the major resistance mechanism of *Klebsiella pneumoniae* to carbapenems. Currently, the common carbapenemase among *K. pneumoniae* clinical strains include Ambler class A, Ambler class B and Ambler class D (eg. *bla*~OXA-48~, and *bla*~OXA-232~). *bla*~KPC-2~ is the most common carbapenemase in class A enzymes which can hydrolyze almost all of β-lactam antibiotics. *bla*~NDM~ is the most common carbapenemase in class B metallo-β-lactamase which can hydrolyze all β-lactam antibiotics except aztreonam. Previous studies have shown the CR-KP strains isolated from children in China mainly produce *bla*~NDM~ \[[@CR21]\]. *bla*~OXA-48~ carbapenemase are predominantly existent in *Klebsiella pneumoniae* isolated in Tokyo and Europe \[[@CR22]\]. In China, *bla*~OXA-181~ and *bla*~OXA-232~ have also been detected among *Klebsiella pneumoniae* clinical strains \[[@CR23], [@CR24]\]~.~

Since CRE are usually extensively drug resistant, infections due to CRE are often associated with a high mortality. Therefore, a serious challenge of anti-infection therapy for CRE has been raised in clinical practice. Studies have revealed that compared to use carbapenems antibiotics alone, in the combination of carbapenems with other antibacterial agents such as tigecycline or polymyxin \[[@CR25]--[@CR28]\], amikacin \[[@CR29]\] or fosfomycin \[[@CR30]\] can considerably improve the outcomes of patient with CR-KP infection. Laurent adopted a combined pharmacotherapy regimen of dual carbapenems to provide a new approach in the treatment of CRE-induced infections \[[@CR31]\]. As a novel β-lactam/β-lactamase inhibitor, studies have shown that ceftazidime-avibactam can successfully cure the infections due to *Enterobacteriaceae* with *bla*~KPC~ \[[@CR32]--[@CR35]\]. Nevertheless, it is worth to be noticed that with the increasing application of ceftazidime-avibactam, the resistant strains and failed cases have been reported \[[@CR6], [@CR7], [@CR36]\]. Our results showed that all of 16 *bla*~KPC-2~ positive and 1 of *bla*~OXA-232~ positive *Klebsiella pneumoniae* were susceptible to ceftazidime-avibactam with MIC~50~ and MIC~90~ for both 8 mg/L. Time-kill assays demonstrated that it showed a significant bactericidal effectiveness for either *bla*~KPC~ or *bla*~OXA-232~ positive *K. pneumoniae* at the concentrations of 2MIC, 4MIC or 8MIC of ceftazidime-avibactam. 1 and Fig. [2](#Fig2){ref-type="fig"}). At 1 MIC of ceftazidime-avibactam, most of *K. pneumoniae* strains started to regrowth within 4--6 h. These results mean that the dosage of ceftazidime-avibactam is very important in the treatment of infections caused by *bla*~KPC~ or *bla*~OXA-232~ positive *K. pneumoniae* \[[@CR37]\].

In this study, 76.7% of *bla*~NDM~ positive *Klebsiella pneumoniae* were resistance to ceftazidime-avibactam with MIC~50~ and MIC~90~ for 64 mg/L and 256 mg/L, respectively. Because avibactam can not inhibit the activity of metallo-β-lactamase, ceftazidime-avibactam monotherapy was ineffective for infections caused by *bla*~NDM-1~ positive *Klebsiella pneumoniae* \[[@CR38]\]. According to the results of time-kill assay, ceftazidime-avibactam combined with aztreonam is necessary for the treatment of infection due to *bla*~NDM~ positive *K. pneumoniae* based on the characteristics of weak hydrolysis capacity of metallo-β-lactamases to aztreonam. Eric Wenzler et al. also demonstrated that the combination of ceftazidime-avibactam and aztreonam had a synergistic bactericidal effect against class B metallo-β-lactamase-producing gram-negative bacteria \[[@CR39]\]. Simultaneously, Benjamin Davido et al. reported that two cases infected either with metallo-β-lactamase-producing *Klebsiella pneumoniae* or *Pseudomonas aeruginosa* were successfully cured by combined administration of ceftazidime-avibactam and aztreonam \[[@CR40]\]. The results of antimicrobial susceptibility testing indicated 90% (27/30) strains showed a synergistic effect for ceftazidime-avibactam combined with aztreonam. After combined with aztreonam, the MICs of ceftazidime-avibactam for 27 strains were reduced 4--256 times than ceftazidime-avibactam alone and all of them were susceptible to ceftazidime-avibactam with MIC ≤8 mg/L. Subsequently, the bactericidal curve tests performed on 12 strains of *Klebsiella pneumoniae* with a synergistic effect were also shown the consistent synergistic bactericidal effects. The reduction of bacterial colonies number was \>2 log~10~ CFU/ mL compared with monotherapy and no colonies were detected after 24 h. In addition to strain of R148 showing the synergism 8 h after combined therapy, three *bla*~NDM~ positive *Klebsiella pneumoniae* clinical strains of R96, R97 and R100 did not demonstrate the synergistic effects after combined use with aztreonam, implying the other mechanisms of drug resistance may exist and require the further investigation in the future.

Conclusions {#Sec14}
===========

In summary, as a compound preparation of novel enzyme inhibitor, ceftazidime-avibactam possesses visible advantages in the treatment of class A and class D type carbapenemase--producing *Klebsiella pneumoniae* clinical isolates. In addition, if combined with aztreonam, it can also play a synergetic bactericidal effects against infections caused by *bla*~NDM~ positive *Klebsiella pneumoniae* clinical strains.
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